Listen to this page using ReadSpeaker

ARVO 2018: Port Delivery System Designed to Reduce Burden of Lucentis Injections for Wet AMD

Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial.

The image on the right shows the port implanted into an eye.


6 Responses to 'ARVO 2018: Port Delivery System Designed to Reduce Burden of Lucentis Injections for Wet AMD'

  1. Susan Patston says:

    I’d like to be kept informed about the procedure.

  2. Jim Knox says:

    I also would like to be kept informed about the procedure.

  3. Roger Tornero says:

    Could the amount of lLucentis being dispensed be regulated or is it a constant outflow?

Leave a Reply

Your email address will not be published. Required fields are marked *

*